Biomarker Analysis in Clinical Trials with R  book cover
1st Edition

Biomarker Analysis in Clinical Trials with R

ISBN 9781138368835
Published April 1, 2020 by Chapman and Hall/CRC
204 Pages - 38 B/W Illustrations

SAVE ~ $24.00
was $120.00
USD $96.00

Prices & shipping based on shipping country


Book Description

The world is awash in data. This volume of data will continue to increase. In the pharmaceutical industry, much of this data explosion has happened around biomarker data. Great statisticians are needed to derive understanding from these data. This book will guide you as you begin the journey into communicating, understanding and synthesizing biomarker data. -From the Foreword, Jared Christensen, Vice President, Biostatistics Early Clinical Development, Pfizer, Inc.

Biomarker Analysis in Clinical Trials with R offers practical guidance to statisticians in the pharmaceutical industry on how to incorporate biomarker data analysis in clinical trial studies. The book discusses the appropriate statistical methods for evaluating pharmacodynamic, predictive and surrogate biomarkers for delivering increased value in the drug development process. The topic of combining multiple biomarkers to predict drug response using machine learning is covered. Featuring copious reproducible code and examples in R, the book helps students, researchers and biostatisticians get started in tackling the hard problems of designing and analyzing trials with biomarkers.


  • Analysis of pharmacodynamic biomarkers for lending evidence target modulation.

  • Design and analysis of trials with a predictive biomarker.

  • Framework for analyzing surrogate biomarkers.

  • Methods for combining multiple biomarkers to predict treatment response.

  • Offers a biomarker statistical analysis plan.

  • R code, data and models are given for each part: including regression models for survival and longitudinal data, as well as statistical learning models, such as graphical models and penalized regression models.

Table of Contents

Section I Pharmacodynamic Biomarkers

1. Introduction

2. Toxicology Studies

3. Bioequivalence Studies

4. Cross-Sectional Profile of Pharmacodynamics Biomarkers

5. Timecourse Profile of Pharmacodynamics Biomarkers

6. Evaluating Multiple Biomarkers

Section II Predictive Biomarkers

7. Introduction

8. Operational Characteristics of Proof-of-Concept Trials

with Biomarker-Positive and -Negative Subgroups

9. A Framework for Testing Biomarker Subgroups in

Confirmatory Trials

10. Cutoff Determination of Continuous Predictive

Biomarker for a Biomarker–Treatment Interaction

11. Cutoff Determination of Continuous Predictive Biomarker

Using Group Sequential Methodology

12. Adaptive Threshold Design

13. Adaptive Seamless Design (ASD)

Section III Surrogate Endpoints

14. Introduction

15. Requirement # 1: Trial Level – Correlation Between

Hazard Ratios in Progression-Free Survival and Overall

Survival Across Trials

16. Requirement # 2: Individual Level – Assess the Correlation

Between the Surrogate and True Endpoints After Adjusting

for Treatment (R2


17. Examining the Proportion of Treatment Effect in AIDS Clinical


18. Concluding Remarks

Section IV Combining Multiple Biomarkers

19. Introduction

20. Regression-Based Models

21. Tree-Based Models

22. Cluster Analysis

23. Graphical Models

Section V Biomarker Statistical Analysis Plan

View More



Nusrat Rabbee is a biostatistician and data scientist at Rabbee & Associates, where she creates innovative solutions to help companies accelerate drug and diagnostic development for patients. Her research interest lies in the intersection of data science and personalized medicine. She has extensive experience in bioinformatics, clinical statistics and high-dimensional data analyses. She has co-discovered the RLMM algorithm for genotyping Affymetrix SNP chips and co-invented a high-dimensional molecular signature for cancer. She has spent over 17 years in the pharmaceutical and diagnostics industry focusing on biomarker development. She has taught statistics at UC Berkeley for 4 years.